文献速递胃肠外科

微创近端胃切除术与全胃切除术治疗近端胃癌及胃食管结合部癌:泛太平洋多中心协作研究3个月随访结果

Transpacific multicenter collaborative study of minimally invasive proximal gastrectomy vs. minimally invasive total gastrectomy for proximal gastric and gastroesophageal junction cancers: 3-month follow-up results.
PubMed 文献 · Surg Endosc · 2025-09-29

这项泛太平洋多中心非随机前瞻性队列研究比较了微创近端胃切除术(MIPG)与微创全胃切除术(MITG)治疗近端胃癌及胃食管结合部癌的症状负担结局。共纳入71例患者,其中64例接受手术(MITG 26例,MIPG 38例)。结果显示两组短期安全性相当,MIPG在术后3个月内未显示出可测量的生活质量优势,包括食欲方面。

要点

  • MIPG与MITG短期安全性相当,并发症、吻合口漏、90天死亡率及切缘阳性率均无显著差异。
  • 术后1个月和3个月,食欲、反流、总症状负担及功能干扰等生活质量指标两组无显著差异。
  • 术后3个月体重轨迹、血红蛋白、白蛋白、维生素B12及胃饥饿素水平两组相当。

核心结论

  • MIPG与MITG在近端胃癌及胃食管结合部癌患者中表现出相当的短期安全性。
  • MIPG在术后3个月内未带来可测量的生活质量优势,包括食欲方面。
  • 长期随访正在进行,以评估潜在的延迟优势。

研究设计与样本

  • 泛太平洋、多中心、非随机、前瞻性队列研究。
  • 2022年至2024年共纳入71例近端胃癌及胃食管结合部癌患者,64例接受手术(MITG 26例,MIPG 38例)。
  • 39例(61%)在亚洲中心治疗,25例(39%)在美国中心治疗。
  • 症状负担数据采用MD Anderson症状量表(MDASI-GI+)收集。

主要发现

  • MITG组平均肿瘤尺寸大于MIPG组(5.7 cm vs. 2.3 cm),印戒细胞组织学比例更高(50% vs. 18%)。
  • MITG与MIPG组手术时间中位数分别为288.5分钟与277.0分钟,术后并发症发生率分别为19%与24%,吻合口漏分别为0%与3%,90天死亡率分别为0%与3%,近端切缘阳性率分别为8%与0%(所有p>0.05)。
  • 术后1个月和3个月,食欲、反流、总症状负担及功能干扰等生活质量指标两组无显著差异。
  • 线性混合效应模型显示,术后3个月内体重轨迹及最高体重下降百分比两组无显著差异。
  • 术后3个月血红蛋白、白蛋白、维生素B12及胃饥饿素水平两组相当。

临床怎么用

  • 对于近端胃癌及胃食管结合部癌,MIPG可作为与MITG短期安全性相当的术式选择。
  • 在术后3个月内,不应期望MIPG相较于MITG能改善食欲或反流相关生活质量。
  • 需结合肿瘤大小、组织学类型等因素个体化选择术式,并关注长期随访结果。

局限性

  • 非随机设计可能导致选择偏倚,如MITG组肿瘤更大、印戒细胞比例更高。
  • 样本量较小(共64例手术患者),可能影响统计效能。
  • 随访时间仅3个月,无法评估长期肿瘤学结局及延迟的生活质量差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total gastrectomy (TG) remains the standard surgical approach for proximal gastric and gastroesophageal junction (P/GEJ) cancers. However, experts increasingly perform proximal gastrectomy (PG) with anti-reflux reconstruction. The benefits of minimally invasive PG (MIPG) over minimally invasive TG (MITG), particularly regarding postoperative quality of life (QoL), remain unclear. METHODS: We conducted a transpacific, multicenter, nonrandomized, prospective cohort study to compare symptom burden outcomes (symptom occurrence, symptom severity, and daily functioning) between MIPG and MITG in patients with P/GEJ cancers. Symptom burden data was collected using the MD Anderson Symptom Inventory (MDASI-GI +). RESULTS: Among 71 patients with P/GEJ cancers enrolled from 2022 through 2024, 64 underwent either MITG (n = 26, 41%) or MIPG (n = 38, 59%). Thirty-nine (61%) patients were treated at Asian centers, and 25 (39%) patients were treated at U.S. CENTERS: Compared to the MIPG patients, the MITG patients had a larger mean tumor size (5.7 vs. 2.3 cm) and a higher prevalence of signet ring cell histology (50 vs. 18%). Operation times were comparable between the MITG and MIPG groups (median: 288.5 vs. 277.0 min), as were the rates of postoperative complications (19 vs. 24%), anastomotic leaks (0 vs. 3%), 90-day mortality (0 vs. 3%), and positive proximal margins (8 vs. 0%, all p > 0.05). QoL data (MDASI-GI +) were collected from at least 95% of patients at all time points. Key metrics related to QoL-appetite, reflux, total symptom burden, and functional interference-did not differ significantly between groups at 1 and 3 months postoperatively. A linear mixed-effects model showed that body-weight trajectories over time did not differ significantly between the MITG and MIPG groups, and there was no significant difference between their highest weight loss percentages within the first 3 months postoperatively. At postoperative month 3, hemoglobin, albumin, vitamin B12, and ghrelin levels were comparable between the groups. CONCLUSION: MIPG and MITG demonstrated equivalent short-term safety, and MIPG did not confer measurable QoL advantages, including in appetite, within 3 months after surgery. Longer-term follow-up is ongoing to evaluate potential delayed advantages. TRIAL REGISTRATION NUMBER: On January 11, 2022, this trial was registered with the Clinical Trials Reporting Program under the registration number NCI-2022-00267 and with ClinicalTrials.gov under the registration number NCT05205343.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Ikoma N, Grotz T, Kawakubo H, et al. Transpacific multicenter collaborative study of minimally invasive proximal gastrectomy vs. minimally invasive total gastrectomy for proximal gastric and gastroesophageal junction cancers: 3-month follow-up results. Surg Endosc. 2025. PMID: 41023216. doi:10.1007/s00464-025-12257-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。